Lucid Diagnostics Q2 revenue rises to $1.5 million; net loss widens to $14.7 million
Lucid Diagnostics reported second quarter 2026 revenue of $1.5 million, up from $1.2 million a year earlier, and a GAAP net loss attributable to common stockholders of $14.7 million, or $(0.08) per share, compared with $7.9 million in the prior-year quarter. The company also said it secured its first laboratory benefit manager coverage policy for its EsoGuard test, but it still awaits a positive draft Medicare coverage policy.
Key points
- Q2 2026 revenue was $1.5 million ($1,474 thousand), up from $1,163 thousand in Q2 2025.
- GAAP net loss attributable to common stockholders was $14.7 million, or $(0.08) per share, versus $7.9 million a year earlier.
- Non-GAAP adjusted loss was $10.9 million, or $(0.06) per share, versus $9.9 million in Q2 2025.
- Cash and cash equivalents were $33.4 million at June 30, 2026, compared with $34.7 million at December 31, 2025.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.